Manufacturer of Controlled Substances; Notice of Application, 30418 [E8-11631]

Download as PDF 30418 Federal Register / Vol. 73, No. 102 / Tuesday, May 27, 2008 / Notices your entire comment—including your personal identifying information—may be made publicly available at any time. While you can ask us in your comment to withhold your personal identifying information from public review, we cannot guarantee that we will be able to do so. Dated: May 20, 2008. Gary D. Cooper, District Manager. [FR Doc. E8–11722 Filed 5–23–08; 8:45 am] BILLING CODE 4310–GG–P DEPARTMENT OF THE INTERIOR Minerals Management Service Extension of Post-Sale Evaluation Period for Central Gulf of Mexico Lease Sale 206 Minerals Management Service (MMS), Interior. ACTION: Notice to Extend Post-Sale Evaluation Period for Central Gulf of Mexico Lease Sale 206. AGENCY: SUMMARY: This notice extends by 30 days, the post-sale evaluation period for Central Gulf of Mexico Lease Sale 206. The Minerals Management Service (MMS) will complete evaluating all the bids received in this sale by July 17, 2008. This action is necessary due to the unusually high number of bids received in this lease sale. DATES: The post-sale evaluation period ends on June 17, 2008. FOR FURTHER INFORMATION CONTACT: David Marin, Regional Supervisor, Resource Evaluation, Gulf of Mexico Region, telephone 504–736–2710. SUPPLEMENTARY INFORMATION: In the Central Gulf of Mexico Sale 206, held March 19, 2008, we received 1057 bids on 615 tracts, 513 tracts of which passed to a second phase requiring additional detailed evaluations. The aggressive bidding activity is due, in part, to the high number of quality prospects on recently expired unexplored tracts in newly established deepwater hydrocarbon plays and to the cost saving technological advances related to hydrocarbon exploration and development in the Gulf of Mexico’s deepwater environment. The unusually high number of bids received on a large number of tracts, and the high volume of exclusively reprocessed data identified on Sale 206, significantly increases the workload for reviewing the adequacy of bids. Consequently, MMS is unable to conduct and complete the bid review process within the 90 days, i.e., by June 17, 2008. Under the provisions of § 256.47(e)(2), MMS is extending the bid evaluation period until July 17, 2008. Dated: May 5, 2008. Lars Herbst, Regional Director, Gulf of Mexico OCS Region. [FR Doc. E8–11711 Filed 5–23–08; 8:45 am] substance intermediates for sale to its customers. Any other such applicant and any person who is presently registered with DEA to manufacture such a substance may file comments or objections to the issuance of the proposed registration pursuant to 21 CFR 1301.33(a). Any such written comments or objections being sent via regular mail should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), Washington, DC 20537, or any being sent via express mail should be sent to Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than July 28, 2008. BILLING CODE 4310–MR–P Dated: May 15, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–11631 Filed 5–23–08; 8:45 am] DEPARTMENT OF JUSTICE BILLING CODE 4410–09–P Drug Enforcement Administration DEPARTMENT OF JUSTICE Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on April 25, 2008, Siegfried (USA), Inc., Industrial Park Road, Pennsville, New Jersey 08070, made application by letter to the Drug Enforcement Administration (DEA) to be registered as a bulk manufacturer of Oripavine(9330), a basic class of controlled substance listed in schedule II. The company will use the above listed controlled substance in the manufacture of other controlled Drug Enforcement Administration Manufacturer of Controlled Substances; Notice of Application Pursuant to § 1301.33(a) of Title 21 of the Code of Federal Regulations (CFR), this is notice that on September 21, 2007, AMRI Rensselaer, Inc., 33 Riverside Avenue, Rensselaer, New York 12144, made application by renewal to the Drug Enforcement Administration (DEA) as a bulk manufacturer of the basic classes of controlled substances listed in schedules I and II: Drug Schedule pwalker on PROD1PC71 with NOTICES Marihuana (7360) ...................................................................................................................................................... Tetrahydrocannabinols (7370) ................................................................................................................................... Amphetamine (1100) ................................................................................................................................................. Lisdexamfetamine (1205) .......................................................................................................................................... Methylphenidate (1724) ............................................................................................................................................. Pentobarbital (2270) .................................................................................................................................................. Hydrocodone (9193) .................................................................................................................................................. Meperidine (9230) ...................................................................................................................................................... Dextropropoxyphene, bulk (non-dosage form) (9273) .............................................................................................. Oxymorphone (9652) ................................................................................................................................................. Fentanyl (9801) .......................................................................................................................................................... The company plans to manufacture bulk controlled substances for use in product development and for VerDate Aug<31>2005 17:22 May 23, 2008 Jkt 214001 distribution to its customers. In reference to drug code 7360 (Marihuana), the company plans to bulk PO 00000 Frm 00044 Fmt 4703 Sfmt 4703 I I II II II II II II II II II manufacture cannabidiol as a synthetic intermediate. This controlled substance will be further synthesized to bulk E:\FR\FM\27MYN1.SGM 27MYN1

Agencies

[Federal Register Volume 73, Number 102 (Tuesday, May 27, 2008)]
[Notices]
[Page 30418]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-11631]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on April 25, 2008, Siegfried 
(USA), Inc., Industrial Park Road, Pennsville, New Jersey 08070, made 
application by letter to the Drug Enforcement Administration (DEA) to 
be registered as a bulk manufacturer of Oripavine(9330), a basic class 
of controlled substance listed in schedule II.
    The company will use the above listed controlled substance in the 
manufacture of other controlled substance intermediates for sale to its 
customers.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such a substance may file comments or 
objections to the issuance of the proposed registration pursuant to 21 
CFR 1301.33(a).
    Any such written comments or objections being sent via regular mail 
should be addressed, in quintuplicate, to the Drug Enforcement 
Administration, Office of Diversion Control, Federal Register 
Representative (ODL), Washington, DC 20537, or any being sent via 
express mail should be sent to Drug Enforcement Administration, Office 
of Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive, Springfield, Virginia 22152; and must be filed no 
later than July 28, 2008.

    Dated: May 15, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E8-11631 Filed 5-23-08; 8:45 am]
BILLING CODE 4410-09-P